Samiksha Jaiswal (Editor)

Jazz Pharmaceuticals

Updated on
Edit
Like
Comment
Share on FacebookTweet on TwitterShare on LinkedInShare on Reddit
Type
  
Private

Industry
  
Biotechnology

COO
  
Russell J. Cox

Traded as
  
NASDAQ: JAZZ

Revenue
  
$340.9 million Q3 2015

Jazz Pharmaceuticals httpswwwjazzpharmacomwpcontentthemesjazz

Key people
  
Bruce C. Cozadd (Chairman and CEO) Kathryn E. Falberg (CFO and Executive Vice President) Suzanne Sawochka Hooper (Executive Vice President and General Counsel) Russell J. Cox (Chief Commercial Officer) and Executive Vice President)

Products
  
Xyrem, FazaClo, FazaClo HD, Luvox CR, Prialt

Stock price
  
JAZZ (NASDAQ) US$ 133.04 +0.08 (+0.06%)9 Mar, 4:00 PM GMT-5 - Disclaimer

Headquarters
  
Dublin, Republic of Ireland

CEO
  
Bruce C Cozadd (Apr 2009–)

Subsidiaries
  
Celator Pharmaceuticals Inc.

Profiles

Jazz pharmaceuticals breaks ground on new manufacturing and development facility in ireland


Jazz Pharmaceuticals PLC (a merger of Jazz Pharmaceuticals and Azur Pharma PLC) is an Ireland-based biopharmaceutical company which specializes of identifying, developing and commercializing pharmaceutical products. It was founded in 2003. One of the company's most significant products is the United States Food and Drug Administration (FDA) approved drug, Xyrem (Sodium Oxybate - another term for the identical substance more commonly referred to as GHB Gamma Hydroxy Butrate).

Contents

In 2007, the company pled guilty to felony charges related to its illegal marketing of Xyrem for off-label use.

The company is also a member of the Pharmaceutical Research and Manufacturers of America (PhRMA).

A g capital s kramer says biotech company jazz pharmaceuticals has a bright future


2010

On February 18, the FDA accepted a new drug application for JZP-6 (Sodium Oxybate) for the treatment of Fibromyalgia In the following December, a new patent was issued for Sodium Oxybate

2011

On September 19, Jazz Pharmaceuticals and Azur Pharma PLC agreed to merge

2012

On April 26, the company acquired EUSA Pharma for $650 million (plus $50 million in milestone payments In September the company successfully sold its Women's Health business to Meda for $95 million In December, the company began clinical trial of intravenous Erwinaze in patients suffering from Acute Lymphoblastic Leukemia

2014

In January, the company announced it would acquire the rare disease drug developer Gentium SpA and its lead product Defitelio for $1 billion

2016

In May, the company announced it would acquire Alizé Pharma II for $20.5 million. At the end of the same month, the company announced its largest acqusition to date, with the purchase of Celator Pharmaceuticals for $1.5 billion.

Acquisition history

The following is an illustration of the company's major mergers and acquisitions and historical predecessors (this is not a comprehensive list):

Products

  • Xyrem – used for excessive daytime sleepiness and cataplexy in narcoleptics.
  • FazaClo (and FazaClo HD) – used in the management of patients severely ill with schizophrenia.
  • Luvox CR – used in the treatment of patients with Obsessive compulsive disorder
  • Parcopa
  • References

    Jazz Pharmaceuticals Wikipedia